Quantcast Align Technology Blows Through Estimates
Search by tag or site Login to my blog ? Start my own blog














TheMoneyBlogs
Home
About
Create your own blog
Contact us
Vote for this blog!

BioHealth Investor

BioHealth Investor (BHI) is a blog and journal focused on providing updated commentary and financial news from the biotech and medical technology industry. BHI's content is featured on Yahoo!Finance, Google Finance, TheStreet.com, SeekingAlpha.com and many other blogs and websites. BHI is also a proud member of The Business of Biotech Network, and the Investors Blog Network.

Align Technology Blows Through Estimates

Posted on 04/27/2007 08:35:27 | Link | Post Comment
by H.S. Ayoub, DMD
BioHealth Investor.com


On Thursday, Align Technology (ALGN), the developer of the Invisalign clear teeth straightening system, blew past analyst estimates.

First quarter 2007 revenue numbers increased by more than 30% to $63.8 million over 1Q of 2006. The company also reported a return to profitability with a $.10 per share during the first quarter.

Analysts were expecting, or "guessing" might be a more accurate description, revenues of $58.5 million with a loss of $.01 per share.

The company also raised its 2007 forecast to earnings of $0.46-$0.55 a share on revenue of $268.4 million to $278.0 million.

Align stock skyrocketed by more than 33% by day end, as the quarterly report hit investors by surprise. The stock price ended trading at $23.60, blowing past the 52-week high of $17.95!

But is this new price level sustainable?

Taking the company's high end of its expected 2007 earnings, $0.55 per share, the current price would be 42x earning! That is taking the company's best expectations. If we assume a $0.46 per share profit level, the current price would be a hefty 51x earnings.

However, we must consider the fact that most high growth stocks tend to have lofty price to earning ratios. A range of 42 to 51 times earnings is not such an amazing number, as long as Align Technology continues its strong push for getting dentists to use Invisalign in their offices.

Now with the OrthoClear fiasco well behind them, Align Technology executives can focus not only on attracting more dentists from the U.S., but from abroad as well. According to the company's latest data about close to 25% of participating dentists were international, but only 74% submitted multiple cases. In contrast, 88% and 87% of U.S. orthodontists and general practitioners were multile submitting doctors respectively.

A small increase in the percentage of international dentists who submit multiple cases, and the continued growth in U.S. doctors, will at the very least justify the current price level. With another earnings surprise next quarter, and a further raising of the yearly forecast, Align Technology stock could very well cross the $30 a share milestone before the end of 2007.



Disclosure: Dr.Ayoub is a practicing general dentist in South Florida, does not own any position in Align Technology stock, and does not have any affiliation, business or otherwise, with the company.


Source: BioHealth Investor.com



RELATED READING:
- Investing In the Growing Dental Industry
- Why Does Procter & Gamble Need a Dental Laser?
- Oragenics Betting on Dental Cavity Vaccine
- Carrington Hopes Dental Market Improves Earnings

______________________
Stock Quote or
Examples
Morpheus Trading - Thu Jul 17, 2008 01:15AM
NOTE: Please click on the charts below to enlarge them if th [read more]
Morpheus Trading - Mon Jul 21, 2008 08:33AM
NOTE: Please click on the charts below to enlarge them if [read more]
The Swing of Things - Thu Jul 17, 2008 09:36AM
I used to make a pretty good living sharing hard won [read more]

PREMIER SPONSORED LINKS

Most Visited Blogs | Most Popular Blogs | Most Recent Blogs | Contact Us | Terms and conditions | Privacy Policy

The columns, articles, message board posts and any other features provided on TheMoneyBlogs.com are provided for personal finance, education and investment information and are not to be construed as investment advice. Under no circumstances does the information in this content represent a recommendation to buy, sell or hold any security. The views and opinions expressed in an article or column are the author's own and not necessarily those of TheMoneyBlogs.com and there is no implied endorsement by TheMoneyBlogs.com of any advice or trading strategy. The analysts and employees or affiliates of TheMoneyBlogs.com may hold positions in the stocks or industries discussed here. Your use of this and all information contained on TheMoneyBlogs.com is governed by the Terms and Conditions of Use. Please click the link to view those terms. Follow this link to read our Editorial Policy.

Copyright © 2008 The Connors Group, Inc.